Group 1: Investor Relations Activity Overview - The company held an earnings briefing on May 9, 2025, via an online platform, attended by investors [3] - Key personnel present included the Chairwoman, General Manager, Financial Officer, and Board Secretary [3] Group 2: Industry and Market Insights - The biotechnology industry is in a growth phase with significant market potential, supported by national policies promoting innovation [4] - The company achieved overseas sales of CNY 14.97 million in 2024, a 95% increase year-on-year due to enhanced participation in international exhibitions and visits to overseas distributors [4] Group 3: Financial Performance and Strategy - The company reported a revenue of CNY 32.66 million in Q1 2025, a 19.08% increase year-on-year, with a net profit of CNY 6.50 million, up 121.46% [10] - The company maintains a healthy financial status with low debt levels, providing strategic flexibility for potential acquisitions [6] Group 4: Shareholder Returns and Dividends - The company plans to distribute a cash dividend of CNY 1.80 per 10 shares, totaling CNY 15.99 million [9] - From 2023 to 2024, the company repurchased 2,637,454 shares for a total of CNY 28.21 million [9] Group 5: Future Growth and Investor Confidence - The company aims to enhance investor confidence through consistent dividends, performance growth, and improved communication with investors [8] - The company emphasizes maintaining a strong brand strategy and high-quality development to align market value with intrinsic value [8]
新芝生物(430685) - 投资者关系活动记录表